Fiduciary Financial Group LLC Grows Position in Sanofi (NASDAQ:SNY)

Fiduciary Financial Group LLC grew its holdings in Sanofi (NASDAQ:SNY) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,174 shares of the company’s stock after purchasing an additional 399 shares during the quarter. Fiduciary Financial Group LLC’s holdings in Sanofi were worth $350,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after acquiring an additional 33,105 shares during the period. Geode Capital Management LLC increased its position in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after purchasing an additional 16,780 shares during the last quarter. GFS Advisors LLC boosted its stake in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after buying an additional 11,655 shares during the period. Legacy Capital Wealth Partners LLC boosted its stake in Sanofi by 114.2% during the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after buying an additional 12,942 shares during the period. Finally, Icon Wealth Advisors LLC boosted its stake in shares of Sanofi by 7,954.4% in the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock valued at $16,873,000 after purchasing an additional 289,144 shares during the period. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on SNY shares. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Sanofi stock opened at $48.45 on Wednesday. The stock has a market cap of $122.96 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a 50 day moving average of $48.53 and a 200-day moving average of $52.11. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the company posted $2.55 EPS. The business’s revenue was up 12.3% compared to the same quarter last year. On average, analysts expect that Sanofi will post 4.06 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.